Pyogenic vertebral osteomyelitis (VO) is
P
yogenic vertebral osteomyelitis (PVO) is a fairly rare but serious infection. The incidence of vertebral osteomyelitis has been estimated at 4 to 10 per 100,000 inhabitants per year in industrialized countries (1, 2) . Its incidence has been on the rise over the past decade because of population aging (3), increased use of invasive spinal procedures (4) , and more effective diagnostic tools (5) . Cases without a confirmed microbiological diagnosis are also becoming more common (5, 6) .
PVO is diagnosed based on symptoms, clinical findings, imaging, and laboratory results. The identification of the microorganisms involved is required to make a definitive diagnosis of PVO (7, 8) . Blood cultures lead to microbiological diagnosis in 40 to 60% of cases (9) . If blood cultures are negative, a percutaneous needle biopsy (PNB) should be performed according to guidelines, and the PNB should be repeated if the results remain negative (10) . The PNB procedure leads to microbiological diagnosis in 43 to 78% of cases (11) , but in 21 to 34% of cases, the causative pathogen is still not identified (12) .
PNB is a fairly safe and minimally invasive procedure, but it is not without risk. Complications occur in 1 to 3% of procedures and include bleeding, neurologic injury, pneumothorax, dural puncture, infection, and the spread of tumor cells along the needle tract (13, 14) . The diagnostic yield of PNB is variable because of failure in the procedure, low-virulence organisms, and prior antibiotic use. Furthermore, the delay to obtain this exam is sometimes long, thus delaying diagnosis and treatment. Although isolation of the causative pathogen is strongly recommended before starting antibiotic treatment, several studies suggest that knowledge of the microorganism involved does not influence the success or duration of therapy and is not associated with fewer sequelae (6, 7, 15) . A recent study suggested that empirical antibiotic therapy can be used without resorting to PNB if blood cultures are negative (16) .
Empirical antibiotic therapy should take into account not only the wide range of microorganisms commonly associated with PVO, but also local susceptibility rates and the likelihood of infection with a resistant organism. The bacterial epidemiology of PVO has been well described. Staphylococcus aureus is the most common pathogen (20 to 80%), followed by Enterobacteriaceae (7 to 33%), streptococci (5 to 20%), and coagulase-negative staphylococci (CNS; 5 to 16%) (9) . However, little is known about the antimicrobial susceptibilities of these pathogens. Susceptibility testing seems to be essential, given the increasing prevalence of resistance to antimicrobial agents in both hospital-and community-acquired infections.
In cases of nondocumented PVO, French guidelines recommend empirical antibiotic combination therapy involving a fluoroquinolone and an antistaphylococcal agent (rifampin, clindamycin, or fusidic acid) (17) . The choice of molecules depends on prescribing patterns. In our center, if empirical therapy is required, we usually use ofloxacin combined with rifampin. Other combinations have been suggested, such as levofloxacin and rifampin (6, 18) , ciprofloxacin and clindamycin (8) , or ciprofloxacin and amoxicillin-clavulanate (7), but the microbiological relevance of these combinations has never been assessed.
The aim of our study was to describe the microorganisms isolated by PNB and to analyze their susceptibility patterns, in order to assess the possibility of empirical combination therapy for the treatment of nonbacteremic PVO patients without resorting to PNB.
(Parts of the manuscript were presented at the 11th ECCMID in Copenhagen in 2015.)
MATERIALS AND METHODS
Study population. From 1 November 2006 through 1 March 2011, 351 patients from 71 medical care centers (infectious diseases, rheumatology, or internal medicine departments) in France were enrolled in a prospective, open, randomized, noninferiority, controlled, multicenter trial that compared treatment with various antibiotics for 6 and 12 weeks in patients with microbiologically confirmed PVO (19) . In this trial, the causative agent was identified by blood cultures and/or image-guided vertebral PNB. Our study focused on patients in whom the causative bacterium had been identified by PNB.
Inclusion criteria and definitions. PVO was diagnosed based on typical radiological features (with magnetic resonance imaging and/or computer tomography [CT] scan) and bacteriological findings. Only nonbacteremic adult patients (Ն18 years old) in whom the causative bacterium had been identified by PNB were included in the analysis. The biopsies were performed before starting antibiotic treatment, and all pyogenic vertebral osteomyelitis cases had microbiological identification. Postoperative PVO was defined by the occurrence of infection in the year following spinal surgery. At least two bacterial cultures yielding the same pathogen were required from different samples taken during the same biopsy (at least three identical specimens were required if the pathogen was a skin bacterium, such as a CNS species, Propionibacterium acnes, or Corynebacteria, Lactobacilllus, or Micrococcus species) (16, 17) . Exclusion criteria were the presence of a vertebral implant, recurrence of PVO, fungal, brucellar or mycobacterial infection, or inability to identify the causative microorganism.
Data collection. A case report form was used to collect data for each patient, including age, sex, comorbidities, clinical symptoms, biological variables, and radiologic abnormalities. For each case, we carefully listed the causative pathogen(s) and its sensitivity to various antimicrobial agents. These descriptive epidemiological data were recorded in Microsoft Excel.
PNB procedure. Image-guided PNB was performed in each inclusion center. Image guidance was performed via fluoroscopy or computed tomography, depending on the standard practice of the center. According to French guidelines, several deep samples (disc and bone) with a large caliber (e.g., 11-gauge) trocar were required when possible, with a minimum of two samples. The specimens were then sent to the respective local laboratory for microbiological analysis.
Laboratory analysis. Each vertebral biopsy specimen was cultured with standard microbiological methods with the calibrated loop technique at local laboratories. Susceptibility testing for different antibiotics was done by the disc-diffusion and MIC methods (Etest, bioMérieux, Lyon, France) when necessary, with breakpoints from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and French microbiological guidelines.
Depending on the bacterial species, the activities of various antimicrobial agents were tested: ␤-lactams (benzylpenicillin, amoxicillin, amoxicillin-clavulanate, piperacillin-tazobactam, oxacillin, a third-generation cephalosporin, ceftazidime, carbapenems); macrolides and lincosamides (erythromycin, pristinamycine, clindamycin); fluoroquinolones (ofloxacin, ciprofloxacin, and levofloxacin), aminoglycosides (kanamycin, tobramycin, gentamicin, and amikacin), glycopeptides (vancomycin, teicoplanin); tetracycline (doxycycline, minocycline); rifampin; fusidic acid; fosfomycin; trimethoprim-sulfamethoxazole; chloramphenicol; linezolid.
Isolated strains were categorized by the laboratory as susceptible (S), intermediate (I), or resistant (R) to antimicrobial agents. Given the risk of treatment failure for intermediate strains, strains classified "I" were reassigned "R," such that all strains were then classified as "S" or "R" to antimicrobial agents. For polymicrobial infections, the findings of antimicrobial susceptibility testing for both types of bacteria were pooled.
Several antibiotic combinations were analyzed: ofloxacin plus rifampin, levofloxacin plus rifampin, ciprofloxacin plus clindamycin, and ciprofloxacin plus amoxicillin-clavulanate. For Staphylococcus spp. and Pseudomonas aeruginosa, strains were categorized "S" to antibiotic combinations if they were susceptible to both antimicrobial agents (except for clindamycin, which can be used as a monotherapy on S. aureus [17] ). For all other species, strains were categorized "S" if they were susceptible to either antimicrobial agent.
Ethics. The French National Agency for the Safety of Medicines and Health Products (AFSSAPS; authorization number 060357-33), the French Data Protection Agency (CNIL), and the institutional review board of Versailles University Hospital (authorization number 06030) approved the study protocol. This trial is registered with EudraCT, number 2006-000951-18, and Clinical Trials.gov, number NCT00764114.
This study was performed in accordance with the Helsinki Declaration and Good Clinical Practice guidelines. Written informed consent for participation in the trial was obtained from all patients.
RESULTS
Over the 4-year period, a definitive microbiological diagnosis was obtained by PNB in 101 patients with PVO, and these individuals were included in the analysis.
Baseline clinical presentation and biological and radiological findings. The baseline clinical, biological, and radiological findings of patients are shown in Table 1 . The sex ratio (M/F) was 2.5. Nearly half of all patients were immunosuppressed because of an underlying comorbidity, including diabetes mellitus (14.5%), alcohol abuse (10%), liver cirrhosis (13%), malignancy (29.2%), malnutrition (4.4%), immunosuppressive therapy (4.4%), and autoimmune disorders (1.5%). None had chronic renal failure. A total of 19 (18.8%) patients developed postoperative PVO.
Symptoms had been present for a median of 82 days. Back pain was the main symptom identified; fever was absent in 76% of cases, and 20% of patients had C-reactive protein (CRP) levels of Ͻ10 mg/liter. Seven patients (6.9%) required a second PNB, and the causative organism in these cases was S. aureus (n ϭ 2), P. acnes (n ϭ 2), Streptococcus equisimilis (n ϭ 1), Klebsiella pneumoniae (n ϭ 1), and Kingella kingae (n ϭ 1).
Causative organism. Table 2 lists the organisms that were isolated. CNS was the main causative pathogen identified (26%), and S. aureus accounted for 21% of isolates. CNS infection was postoperatively acquired in 46% of cases (n ϭ 12). Logistic regression showed that the variables "postoperative" and "SCN" were statistically related (P Ͻ 0.001). Among streptococcal infections, two were due to S. pneumoniae and two to enterococci. All seven cases of polymicrobial infection included CNS and another organism: S. aureus (n ϭ 3), Burkholderia cepacia (n ϭ 1), P. acnes (n ϭ 1), Streptococcus anginosus (n ϭ 1), or another CNS (n ϭ 1). Postoperatively acquired PVO was due to SCN in 63.1% (n ϭ 12) of cases; other causative organisms were P. acnes (n ϭ 2), Enterobacter aerogenes (n ϭ 1), or S. aureus (n ϭ 1) or polymicrobial (n ϭ 3).
Antimicrobial susceptibility testing. Antimicrobial susceptibility testing of microorganisms isolated from percutaneous needle biopsy specimens are shown in Table 3 . Among the 21 S. aureus isolates identified, only one was methicillin resistant, whereas 27% of CNS were resistant to methicillin and 20% to fluoroquinolones. All Enterobacteriaceae were susceptible to a third-generation cephalosporin, but 38.5% were resistant to fluoroquinolones.
In vitro activities of the antimicrobial agents. Regarding fluoroquinolones, levofloxacin was active against 79.3% of all isolated strains, ciprofloxacin was active against 63.4%, and ofloxacin was active against 60.4%. Regarding other broad-spectrum agents, amoxicillin-clavulanate (and by extension, ampicillin-sulbactam, which has a similar spectrum) was effective against 83% of isolated strains, cefazolin was effective against 68%, a third-generation cephalosporin was effective against 88%, piperacillin-tazobactam was effective against 91.9%, carbapenem was effective against 91%, and trimethoprim-sulfamethoxazole was effective against 81.5% of all isolated strains.
Relevance of empirical combination therapy according to pathogen or patient profile. Overall, empirical antibiotic combination therapy was effective in nearly 75% of cases, except for the combination of ofloxacin plus rifampin, which was effective in only 58% of cases (Fig. 1) . The worst results were obtained for Enterobacteriaceae and uncommon pathogens.
We divided patients according to their initial presentation and analyzed the activity of empirical combination therapy in each group (Fig. 2) . None of the combinations was effective in more than 75% of cases.
DISCUSSION
Here, we found that standard empirical combination therapy was able to treat, at most, 77% of isolated pathogens. The different antibiotic combinations gave similar results, except for ofloxacinrifampin, which was effective in only 58% of cases. CNS was the most common causative pathogen, accounting for 26% of isolates, and thus presented the main challenge to empirical therapy. The clinical and biological presentations of the study population were fairly insidious, with a longer duration of symptoms before diagnosis, less fever, and lower inflammation than typically described for PVO. This finding is probably related to the high percentage of cases of postoperatively acquired PVO. CNS was the most common causative pathogen of nonbacteremic PVO (26%), whereas S. aureus accounted for only 21% of isolates. This unusual distribution is also attributable to the high percentage of cases of postoperatively acquired PVO. The identity and relative proportion of the remaining bacterial isolates was consistent with previously published data. The prevalence of multidrug-resistant bacteria was low in our population. In fact, only one strain of S. aureus was methicillin resistant, which contrasts with previous studies, in which MRSA has been reported in 19.2 to 53.3% of cases of PVO (20) (21) (22) (23) (24) (25) (26) . Similarly, we did not isolate any extended-spectrum ␤-lactamase (ESBL)-producing Enterobacteriaceae, which is inconsistent with recent data showing an increase in resistant strains of Enterobacteriaceae. In a sample of 65 patients with PVO caused by Gram-negative bacteria, Ki-Ho Park et al. found that 8.5% of cases involved ESBL-producing bacteria (27) . Furthermore, a French study reported that the prevalence of ESBL-producing bacteria was 6% in 77 cases of osteomyelitis caused by Gramnegative bacteria (18) . In contrast, we found that nearly 40% of Enterobacteriaceae were resistant to fluoroquinolones, which is higher than recently reported (18, 27) . Like multidrug-resistant organisms (MDRO), CNS are also causing an increasing number of cases of PVO. CNS have natural and acquired resistance to many agents and are becoming a major challenge for empirical antibiotic therapy. To assess the suitability of empirical antibiotic therapy for nonbacteremic PVO, we compared several antibiotic combinations suggested in the literature for the treatment of nondocumented PVO. Fluoroquinolones appear to be the treatment of choice for bone and joint infections, because of their broad spectrum, high oral bioavailability, and good bone penetration, and a fluoroquinolone was thus included in all tested combinations. In our study, levofloxacin was more effective than other fluoroquinolones, probably because of its activity against strepto- 
FIG 1
Relevance of empirical combination therapy according to pathogen for the treatment of nonbacteremic patients with pyogenic vertebral osteomyelitis.
SCN, coagulase-negative staphlococci, SA, S. aureus; Strepto, streptococci; Eb, Enterobacteriaceae. "Other" organisms included Actinomyces (n ϭ 1), Aerococcus urinae (n ϭ 1), Eikenella corrodens (n ϭ 1), Haemophilus aphrophilus (n ϭ 1), Kingella kingae (n ϭ 1), Neisseria sicca (n ϭ 1), Propioribacterium acnes (n ϭ 4), and Pseudomonas aeruginosa (n ϭ 2).
cocci. As suggested by British guidelines (8), we tested the combination of amoxicillin-clavulanate and clindamycin. This combination was effective against 77% of isolated strains. However, amoxicillin-clavulanate is not routinely used in current French practice, because it shows only moderate bone diffusion and is not recommended in the French guidelines (17) . Overall, except for the combination of ofloxacin and rifampin, all other combinations were effective against approximately 75% of isolated strains. Therefore, despite the very low prevalence of multidrug-resistant bacteria in our study, there is still a risk of microbiological failure in a quarter of cases. Independent risk factors for adverse outcome include a delay in diagnosis of Ͼ2 months, paralysis or motor weakness, and a hospital-acquired infection (9); however, a long delay before the initiation of appropriate antibiotic therapy also appears to be associated with a poor prognosis (26) . In addition, intolerance to antibiotic treatment is common and occurred in 21 (6%) patients of the 351 patients of the original trial (19) . If the causative microorganism is unknown, it is difficult to propose a second-line treatment in cases of intolerance. In a Korean study, in cases of nondocumented PVO, cefazolin was administered to patients with hematogenous PVO and vancomycin was administered to those with postoperative or procedure-related PVO. In both groups of patients, the outcome was similar to that for documented PVO, and those authors concluded that antibiotics selected according to the etiological setting can be used in cases of culture-negative PVO (15) . We also tried to propose an empirical combination therapy based on comorbidities, etiology, or inflammatory markers. However, none of the combinations gave satisfactory results, although the small sizes of the subgroups prevented us from making definitive conclusions. PNB is safe and reliable. The diagnostic yield of this procedure is variable, ranging from 43 to 78% (11), depending on the exact method used. In our experience, fluoroscopy-guided biopsy performed by experienced interventional radiologists, under conscious sedation and local anesthesia, enables several deep samples (disc and bone) to be taken with a large-caliber (11G) trocar and is associated with a high diagnostic yield. Percutaneous biopsy of musculoskeletal lesions can be performed either by fine needle aspiration (FNA) or core needle biopsy (CNB), depending on the diameter of the needle. In a study examining the use of FNA and CNB biopsies in 359 patients with muscoloskeletal lesions, the accuracy of CNB was significantly higher than that of FNB (Ͼ70% versus 60%, respectively) (28) . Fluoroscopy is preferred by most radiologists at our institution, because it is faster, more available, makes it easy to maintain asepsis, and uses less radiation than CT.
Furthermore, PVO is diagnosed according to several lines of evidence: clinical, biological, radiological, and histological. Definitive diagnosis requires the isolation of a causative pathogen or histological confirmation (8) . If biopsy cultures fail to show an organism, histological analysis can often confirm the diagnosis. Moreover, this approach sometimes enables the diagnosis of noninfectious diseases, for which imaging results may be inconclusive (29) (30) (31) (32) .
This study had some limitations. First, the aim of the study was to propose an empirical antibiotic therapy for cases of nonbacteremic PVO, without resorting to PNB. This included both patients with a positive PNB result and those with a negative PNB result. However, we examined only patients with a positive PNB specimen, which may limit the generalizability of our results. Nonetheless, the antibiotic combinations that we tested are recommended to treat nondocumented PVO. Another limitation is that the microbiological samples were analyzed in different laboratories (i.e., the respective laboratory of each inclusion center), which may have led to heterogeneity in the interpretation of susceptibility testing. However, antimicrobial susceptibility testing is controlled by French microbiological guidelines, under the authority of EU-CAST, which guarantees consistency in our results. Finally, we investigated antibiotic activity in vitro, which does not necessarily reflect antibiotic effectiveness in vivo. However, we evaluated the molecules usually recommended for the treatment of PVO. This is the largest study to document bacteria in patients with nonbacteremic PVO, and it is the first to test the antimicrobial susceptibility of all pathogens isolated and to assess the efficacy of empirical antibiotic therapy. At best, in an environment with few strains of multidrug-resistant bacteria, empirical antibiotic therapy effectively covers 77% of isolated pathogens. Given the wide range of potential pathogens in patients with PVO and the increase in antimicrobial resistance, we argue that the causative agent should be determined. If PNB is not possible, an empirical combination of a fluoroquinolone (ideally levofloxacin) and clindamycin or rifampin can be used. However, in such cases, close monitoring is essential, because the risk of failure is 25%. An unfavorable outcome suggests resistance to antibiotics or an incorrect diagnosis. In such cases, microbiological and histological analyses are necessary, and biopsies or surgery are then required.
Conclusion. A "perfect" empirical antibiotic therapy does not exist. If PNB is not possible, we recommend the use of a fluoroquinolone combined with clindamycin or rifampin. However, causative bacteria should be identified if possible, because of the moderate (25%) risk of treatment failure with empirical therapy. Furthermore, in this era of emergence of MDR organisms, good use of antibiotic treatment, especially targeted therapy, should be promoted. PNB remains a necessary procedure.
